BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 7741644)

  • 1. The beneficial effect of low initial dose and gradual increase of erythropoietin treatment in hemodialysis patients.
    Walter J; Gål J; Taraba I
    Artif Organs; 1995 Jan; 19(1):76-80. PubMed ID: 7741644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravenous erythropoietin (rHuEPO) administration increases plasma endothelin and blood pressure in hemodialysis patients.
    Carlini R; Obialo CI; Rothstein M
    Am J Hypertens; 1993 Feb; 6(2):103-7. PubMed ID: 8471228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Efficacy and safety of long-term erythropoietin therapy in chronic hemodialysis patients with renal anemia].
    Ohkubo M; Ishimitsu T; Kawaguchi T; Abe M; Yagi S
    Nihon Jinzo Gakkai Shi; 1993 Feb; 35(2):171-7. PubMed ID: 8315880
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-dose erythropoietin is effective and safe in children on continuous ambulatory peritoneal dialysis.
    Yalçinkaya F; Tümer N; Cakar N; Ozkaya N
    Pediatr Nephrol; 1997 Jun; 11(3):350-2. PubMed ID: 9203190
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A 6-month study of low-dose recombinant human erythropoietin alone and in combination with androgens for the treatment of anemia in chronic hemodialysis patients.
    Gaughan WJ; Liss KA; Dunn SR; Mangold AM; Buhsmer JP; Michael B; Burke JF
    Am J Kidney Dis; 1997 Oct; 30(4):495-500. PubMed ID: 9328363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of hyperparathyroidism on response to erythropoietin in children on dialysis.
    Belsha CW; Berry PL
    Pediatr Nephrol; 1998 May; 12(4):298-303. PubMed ID: 9655362
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and blood rheologic stability in erythropoietin-treated predialysis patients.
    Brown CD; Friedman EA
    Am J Nephrol; 1990; 10 Suppl 2():29-33. PubMed ID: 2260615
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of the anemia of chronic renal failure with subcutaneous recombinant human erythropoietin.
    Watson AJ; Gimenez LF; Cotton S; Walser M; Spivak JL
    Am J Med; 1990 Oct; 89(4):432-5. PubMed ID: 2220877
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of anaemia in dialysis patients with unit dosing of darbepoetin alfa at a reduced dose frequency relative to recombinant human erythropoietin (rHuEpo).
    Locatelli F; Canaud B; Giacardy F; Martin-Malo A; Baker N; Wilson J
    Nephrol Dial Transplant; 2003 Feb; 18(2):362-9. PubMed ID: 12543893
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subcutaneous recombinant human erythropoietin in hemodialysis and continuous ambulatory peritoneal dialysis.
    Pais MJ; Gaspar A; Santana A; Bruges M; Simões J
    Perit Dial Int; 1993; 13 Suppl 2():S541-3. PubMed ID: 8399660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of low-dose subcutaneous erythropoietin in hemodialysis patients.
    Parker KP; Mitch WE; Stivelman JC; Macon EJ; Bailey JL; Sands JM
    J Am Soc Nephrol; 1997 Feb; 8(2):288-93. PubMed ID: 9048348
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved response to erythropoietin in peritoneal dialysis patients as compared to hemodialysis patients: role of iron deficiency.
    Raja R; Bloom E; Johnson R; Goldstein M
    Adv Perit Dial; 1994; 10():135-8. PubMed ID: 7999811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of low dose recombinant human omega erythropoietin (rHuEPO) on anaemia in patients on hemodialysis.
    Acharya VN; Sinha DK; Almeida AF; Pathare AV
    J Assoc Physicians India; 1995 Aug; 43(8):539-42. PubMed ID: 8772973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Practical approach to initiation of recombinant human erythropoietin therapy and prevention and management of adverse effects.
    Abraham PA
    Am J Nephrol; 1990; 10 Suppl 2():7-14. PubMed ID: 2260619
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of recombinant human erythropoietin (rHuEPO) on nutritional status of hemodialysis patients: investigation of direct anabolic effects of rHuEPO.
    Usuba T; Kuno T; Higuchi T; Kikuchi F; Nagura Y; Kanmatsuse K; Takahashi S
    Nihon Jinzo Gakkai Shi; 1994 Nov; 36(11):1288-95. PubMed ID: 7853762
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endotoxin-free dialysate improves response to erythropoietin in hemodialysis patients.
    Matsuhashi N; Yoshioka T
    Nephron; 2002; 92(3):601-4. PubMed ID: 12372943
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subcutaneous recombinant human erythropoietin in chronic renal allograft dysfunction.
    Aufricht C; Marik JL; Ettenger RB
    Pediatr Nephrol; 1998 Jan; 12(1):10-3. PubMed ID: 9502558
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Double-blind, placebo-controlled study of the therapeutic use of recombinant human erythropoietin for anemia associated with chronic renal failure in predialysis patients. The US Recombinant Human Erythropoietin Predialysis Study Group.
    Am J Kidney Dis; 1991 Jul; 18(1):50-9. PubMed ID: 2063855
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapy of renal anemia in children and adolescents with recombinant human erythropoietin (rHuEPO).
    Campos A; Garin EH
    Clin Pediatr (Phila); 1992 Feb; 31(2):94-9. PubMed ID: 1544282
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Correction of anemia in chronic kidney failure with lyophilized recombinant human erythropoietin using a subcutaneous approach].
    Amar M; Cendoroglo Neto M; Canziani ME; Nadaletto MA; Ajzen H; Draibe SA
    Rev Assoc Med Bras (1992); 1994; 40(2):101-7. PubMed ID: 7820145
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.